As excitement around ChatGPT and other generative AI programs grows, one company, ZoomRx, has launched its own tool to help transform how pharma analyzes data coming out of medical congresses.
The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses
ZoomRx Has Tweaked ChatGPT For Pharma
ChatGPT’s ability to perform sophisticated analysis and writing tasks has taken the world by storm, and now one developer has launched its own AI aimed at revolutionizing pharma’s business intelligence functions.
More from Business
Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.
The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).
Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.
The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.
More from Scrip
The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.
The new year has already brought multiple deals for China-originated antibody-drug conjugates in the DLL3 class, which companies in the country dominate.
CARsgen's anti-Claudin 18.2 CAR-T therapy satricabtagene autoleucel has met its endpoint in a pivotal Phase II trial in later-stage gastric/gastroesophageal junction adenocarcinoma, paving the way for a China NDA filing.